
Loading, please wait...

Loading, please wait...

A review determined the benefit of vedolizumab and TNF-α inhibitors in patients with steroid-refractory microscopic colitis (MC) in 14 studies involving 164 patients. Results exhibited a clinical remission rate of 63.5%, 57.8% & 39.3% for vedolizumab, infliximab, and adalimumab, respectively. Discontinuation of therapy due to biological adverse events was 12.2%, 32.9%, and 23% for vedolizumab, infliximab, and adalimumab groups, respectively.

Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.


A review determined the benefit of vedolizumab and TNF-α inhibitors in patients with steroid-refractory microscopic colitis (MC) in 14 studies involving 164 patients. Results exhibited a clinical remission rate of 63.5%, 57.8% & 39.3% for vedolizumab, infliximab, and adalimumab, respectively. Discontinuation of therapy due to biological adverse events was 12.2%, 32.9%, and 23% for vedolizumab, infliximab, and adalimumab groups, respectively.
2 months ago

A clinical comparison of extravascular and subcutaneous implantable cardioverter-defibrillators, detailing patient selection, pacing capabilities, and implantation nuances.
Today

A premature neonate developed upper limb compartment syndrome after uterine rupture extruded the arm through a scar defect. Conservative management with continuous monitoring yielded complete functional recovery and normal limb growth at 10-year follow-up, highlighting non-operative safety in selected cases.
Today

A meta-analysis of 13 propensity score-matched studies shows ViV-TAVR delivers lower early mortality and reduced bleeding compared to redo-SAVR for degenerated bioprosthetic aortic valves, though long-term hemodynamics warrant careful anatomical and patient-centered evaluation.
Today

Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Yesterday

The All-India Food Processors' Association has approached the Supreme Court to oppose FSSAI's proposed per-100g benchmark for front-of-pack warning labels, advocating instead for a per-serving threshold. We explore the regulatory showdown, nutritional evidence, and implications for clinical lifestyle counseling.
Today